Pembrolizumab (Keytruda®) for adjuvant treatment of RCC. HTA ID: 22026

Assessment Status NCPE Assessment Process Complete
HTA ID 22026
Drug Pembrolizumab
Brand Keytruda®
Indication Is indicated as monotherapy for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Assessment Process
Rapid review commissioned 22/04/2022
Rapid review completed 01/06/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 01/07/2022
Pre-submission consultation with Applicant 06/09/2022
Full submission received from Applicant 23/03/2023
Preliminary review sent to Applicant 08/12/2023
NCPE assessment re-commenced 18/01/2024
Factual accuracy sent to Applicant 11/04/2024
NCPE assessment re-commenced 18/04/2024
NCPE assessment completed 29/04/2024
NCPE assessment outcome The NCPE recommends that pembrolizumab (Keytruda®) be considered for reimbursement, for this indication, if cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.